Search Prime Grants

HT9425261E107

Project Grant

Overview

Grant Description
Deciphering the role of PIK3CA mutations in tumorigenesis of HER2-positive breast cancer
Awardee
Thomas Jefferson University
Funding Goals
BREAST CANCER RESEARCH PROGRAM
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Awarding / Funding Agency
Defense Health Agency (DHA) [DoD]
Place of Performance
Philadelphia, Pennsylvania 191075567 United States
Geographic Scope
Single Zip Code
Related Opportunity
DoD Breast Cancer Breakthrough Award Levels 1 and 2 (HT942525BCRPBTA12)
Thomas Jefferson University was awarded Project Grant HT9425261E107 worth $1,998,484 from Defense Health Agency in September 2026 with work to be completed primarily in Philadelphia Pennsylvania United States. The grant has a duration of 3 years and was awarded through assistance program 12.420 Military Medical Research and Development. The Project Grant was awarded through grant opportunity DoD Breast Cancer Breakthrough Award Levels 1 and 2.

Status
(Ongoing)

Last Modified 5/28/26

Period of Performance
9/1/26
Start Date
8/31/29
End Date
0% Complete

Funding Split
$2.0M
Federal Obligation
$0.0
Non-Federal Obligation
$2.0M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to HT9425261E107

Additional Detail

Award ID FAIN
HT9425261E107
SAI Number
None
Award ID URI
None
Awardee Classifications
Private Institution Of Higher Education
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Other
Awarding Office
HT9425 ARMY MED RES ACQ ACTIVITY
Funding Office
HT0989 CONG DIR MED RES PRGM / CDMRP - MM
Awardee UEI
R8JEVL4ULGB7
Awardee CAGE
0GD96
Performance District
PA-02
Senators
Robert Casey
John Fetterman
Modified: 5/28/26